A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on Hemodialysis

Inclusion Criteria: • End stage renal disease maintained on outpatient hemodialysis at a healthcare center for \> 3 months from screening with hemodialysis at least 3 times per week for a minimum of 9 hours per week of prescribed treatment time and plan to continue this throughout the study. Exclusion Criteria: * Participants with a history of major medical event (previous acute coronary syndrome, stroke or transient ischemic attack or systemic thromboembolic event) within 3 months of screening, major surgery within 3 months of screening, or new major physical examination finding except for documented atrial fibrillation * Active bleeding within the past 3 months from screening or documented bleeding diathesis (excluding uremia), coagulopathy, or recent prolonged compression time at arteriovenous fistula * Screening values of: * Platelet count \< 150,000 cells per millimeter cube (cells/mm\^3) * \< 180,000 cells/mm\^3 for platelet function/activation subgroup * International normalized ratio (INR) \> 1.4 * Activated partial thromboplastin time (aPTT) \> upper limit of normal (ULN) * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 x ULN * Total bilirubin \> ULN * Factor XI (FXI) activity \< 0.3 units per milliliter (U/mL) * Malignancy within 5 years, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated. Participants with malignancies that have been treated with curati…